The Committee on Safety of Medicines reviewed Dr Peter Jones' letter regarding AIDS and the heat treatment of clotting factor and advised that there was insufficient evidence for action to be taken on any specific product. Read more about The Committee on Safety of Medicines reviewed Dr Peter Jones' letter regarding AIDS and the heat treatment of clotting factor and advised that there was insufficient evidence for action to be taken on any specific product.
A H Woodhead wrote to all Blood Transfusion Service directors about a batch of Factorate recalled by Armour Pharmaceuticals. Read more about A H Woodhead wrote to all Blood Transfusion Service directors about a batch of Factorate recalled by Armour Pharmaceuticals.
Dr Peter Foster was head of the R&D Department of the SNBTS PFC. Read more about Dr Peter Foster was head of the R&D Department of the SNBTS PFC.
Clinical trials of Z8 were delayed due to a question about compensation to patients who might be harmed during the trials raised by Prof Ludlam, supported by all of Scotland's haemophilia doctors. Read more about Clinical trials of Z8 were delayed due to a question about compensation to patients who might be harmed during the trials raised by Prof Ludlam, supported by all of Scotland's haemophilia doctors.
PFC experienced issues with the freeze drying process in relation to the production of Z8. Read more about PFC experienced issues with the freeze drying process in relation to the production of Z8.
PFC heat treated products for 24 hours (extended from 2 hours). Read more about PFC heat treated products for 24 hours (extended from 2 hours).
PFC heat treated its existing 12-month stock of Factor 8 batches manufactured as early as October 1983. Read more about PFC heat treated its existing 12-month stock of Factor 8 batches manufactured as early as October 1983.
PFC and SNBTS prioritised dry heat treatment over pasteurisation after the the data presented at Groningen showed that it could inactivate HTLV-3. Read more about PFC and SNBTS prioritised dry heat treatment over pasteurisation after the the data presented at Groningen showed that it could inactivate HTLV-3.
PFC produced 11 pilot batches of "ZHT" and tested their clinical validity in late 1983. Read more about PFC produced 11 pilot batches of "ZHT" and tested their clinical validity in late 1983.